At the intersection of artificial intelligence, sovereign capital, and biological science, Iambic Therapeutics has stepped toward public markets — a move that reflects not merely one company's ambitions, but a broader renegotiation of who funds the future of medicine and why. Backed by Nvidia and Qatar's sovereign wealth fund, the biotech firm's US IPO filing arrives as institutional investors, long cautious after years of sector volatility, begin once again to see life sciences as a worthy frontier. The market's response will say as much about the era as it does about the company.
Nvidia-backed Iambic Therapeutics files for US IPO amid biotech surge
Economy & Finance